Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that affects white blood cells called lymphocytes. There are two main types of lymphocytes: B-cell lymphocytes (B cells) and T-cell ...
Offering a Sense of Hope for Diffuse Large B-cell Lymphoma The Evolving Role of Bispecific Antibodies in Diffuse Large B-cell Lymphoma ...
B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...
AbbVie (ABBV) and Genmab (GMAB) announce a late-stage trial setback for bispecific antibody, Epkinly in diffuse large B-cell ...
How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems. People with FL ...
Deep Origin docking software and molecular dynamics simulations pinpointed the lead compound from a 17-compound libraryComputational results ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results